AUGX / Augmedix, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

AUGX / Augmedix, Inc. / Samjo Management, LLC Passive Investment

SC 13G/A 1 d1151772013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate

AUGX / Augmedix, Inc. / Beryl Capital Management LLC Passive Investment

SC 13G/A 1 augx13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40890 AUGMEDIX, INC. (Exact name of registrant as specified in its chart

AUGX / Augmedix, Inc. / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-9980 (Name

As filed with the Securities and Exchange Commission on October 2, 2024

POS AM As filed with the Securities and Exchange Commission on October 2, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 2, 2024

POS AM 1 d848728dposam.htm POS AM As filed with the Securities and Exchange Commission on October 2, 2024 Registration No. 333-264337 Registration No. 333-251310 Registration No. 333-272081 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-264337 Post-Effective Amendment No. 2 to Form S-1 on Form S-3 Re

SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AUGMEDIX, INC. ARTICLE ONE

Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AUGMEDIX, INC. ARTICLE ONE The name of the corporation is Augmedix, Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address

As filed with the Securities and Exchange Commission on October 2, 2024

As filed with the Securities and Exchange Commission on October 2, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 2, 2024

As filed with the Securities and Exchange Commission on October 2, 2024 Registration No.

SECOND AMENDED AND RESTATED AUGMEDIX, INC. A Delaware corporation (Adopted as of October 2, 2024) ARTICLE I

Exhibit 3.2 Execution Version SECOND AMENDED AND RESTATED BYLAWS OF AUGMEDIX, INC. A Delaware corporation (Adopted as of October 2, 2024) ARTICLE I OFFICES Section 1. Offices. In addition to the corporation’s registered office set forth in the certificate of incorporation, the Board of Directors may at any time establish other offices at any place or places where the corporation is qualified to do

As filed with the Securities and Exchange Commission on October 2, 2024

As filed with the Securities and Exchange Commission on October 2, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 2, 2024

POS AM As filed with the Securities and Exchange Commission on October 2, 2024 Registration No.

As filed with the Securities and Exchange Commission on October 2, 2024

As filed with the Securities and Exchange Commission on October 2, 2024 Registration No.

Commure Completes Merger with Augmedix

Exhibit 99.1 Commure Completes Merger with Augmedix San Francisco, CA – October 2, 2024 – Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix’s special meeting of stock

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 Augmedix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 Augmedix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 Augmedix, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 Augmedix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 Augmedix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

EIGHTH OMNIBUS AMENDMENT

Exhibit 10.1 EIGHTH OMNIBUS AMENDMENT This Eighth Omnibus Amendment (“Eighth Omnibus Amendment”) is made and entered into as of July 1, 2024 (“Amendment Effective Date”), by and between, on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (“Augmedix”) and, on the other hand, Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Augmedix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee  Rate   Amount of  Filing Fee Fees to

Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Augmedix, Inc.

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024 SAN FRANCISCO, August 12, 2024 - Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

Voting and Support Agreement, dated July 19, 2024, by and among Commure, Inc. Anderson Merger Sub, Inc. and

Exhibit 10.5 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 19, 2024, is by and among Commure, Inc., a Delaware corporation (“Parent”), Anderson Merger Sub, a Delaware corporation and a wholly-owned direct subsidiary of Parent (“Merger Sub”), and the undersigned stockholder (the “Stockholder”). WHEREAS, the Stockholder is, as o

Press release dated August 12, 2024.

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024 SAN FRANCISCO, August 12, 2024 - Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024.

Voting and Support Agreement, dated July 19, 2024, by and among Commure, Inc. Anderson Merger Sub, Inc. and

Exhibit 10.6 Execution Version CONFIDENTIAL VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 19, 2024, is by and among Commure, Inc., a Delaware corporation (“Parent”), Anderson Merger Sub, Inc., a Delaware corporation and a wholly-owned direct subsidiary of Parent (“Merger Sub”), and the undersigned stockholder (the “Stockholder”). WHEREAS, the S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 AUGMEDIX, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

, RAF, L.P., Redmile Capital Fund, LP, Redmile Capital Offshore Master Fund, Ltd, Redmile Strategi

Exhibit 10.4 Execution Version CONFIDENTIAL VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 19, 2024, is by and among Commure, Inc., a Delaware corporation (“Parent”), Anderson Merger Sub, Inc., a Delaware corporation and a wholly-owned direct subsidiary of Parent (“Merger Sub”), and the undersigned stockholder (the “Stockholder”). WHEREAS, the S

AUGX / Augmedix, Inc. / Beryl Capital Management LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) July 19, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Augmedix to Join Forces with Commure Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure

Exhibit 99.1 Augmedix to Join Forces with Commure Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure SAN FRANCISCO, July 19, 2024 – Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement

Agreement and Plan of Merger, dated July 19, 2024, by and among Commure, Inc., Anderson Merger Sub, Inc. and Augmedix, Inc.*

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among COMMURE, INC. ANDERSON MERGER SUB, INC. and AUGMEDIX, INC. Dated as of July 19, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 14 1.3 Certain Interpretations 17 Article II THE MERGER 19 2.1 The Merger 19 2.2 The Effective Time 19 2.3 The Closing 19 2.4

Form of Voting and Support Agreement.

Exhibit 10.1 FORM CONFIDENTIAL VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 19, 2024, is by and among Commure, Inc., a Delaware corporation (“Parent”), Anderson Merger Sub, Inc., a Delaware corporation and a wholly-owned direct subsidiary of Parent (“Merger Sub”), and the undersigned stockholder (the “Stockholder”). WHEREAS, the Stockholder is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Press Release, dated July 19, 2024.

Exhibit 99.1 Augmedix to Join Forces with Commure Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure SAN FRANCISCO, July 19, 2024 – Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Augmedix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction (Commission File Number) (IRS Employer o

AUGX / Augmedix, Inc. / Redmile Group, LLC - SC 13D/A Activist Investment

SC 13D/A 1 tm2419821d1sc13da.htm SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 Sa

Form of Voting and Support Agreement.

EX-10.1 3 ea020961401ex10-1augmedix.htm FORM OF VOTING AND SUPPORT AGREEMENT Exhibit 10.1 FORM CONFIDENTIAL VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 19, 2024, is by and among Commure, Inc., a Delaware corporation (“Parent”), Anderson Merger Sub, Inc., a Delaware corporation and a wholly-owned direct subsidiary of Parent (“Merger Sub”), and

Voting and Support Agreement, dated July 19, 2024 by and among Parent, Merger Sub, and the Redmile Funds

EX-99.18 2 tm2419821d1ex99-18.htm EXHIBIT 99.18 Exhibit 99.18 Execution Version CONFIDENTIAL VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of July 19, 2024, is by and among Commure, Inc., a Delaware corporation (“Parent”), Anderson Merger Sub, Inc., a Delaware corporation and a wholly-owned direct subsidiary of Parent (“Merger Sub”), and the undersigne

2024, by and among Commure, Inc., Anderson Merger Sub, Inc. and Augmedix, Inc. (incorporated by reference to Exhibit 2.1 to the Current

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among COMMURE, INC. ANDERSON MERGER SUB, INC. and AUGMEDIX, INC. Dated as of July 19, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 14 1.3 Certain Interpretations 17 Article II THE MERGER 19 2.1 The Merger 19 2.2 The Effective Time 19 2.3 The Closing 19 2.4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Augmedix, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Augmedix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction (Commission File Number) (IRS Employer o

First Amendment to Warrant to Purchase Stock

FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK This FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK (this “Amendment”) is made as of June 26, 2024 by and between FIRST CITIZENS EQUITY INVESTMENTS, LLC (“Holder”) and AUGMEDIX, INC.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 26, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

Second Amendment to Loan and Security Agreement

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of June 26, 2024, by and between (i) SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“Bank”), (ii) AUGMEDIX, INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (C

AUGX / Augmedix, Inc. / Samjo Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Augmedix Reiterates Second Quarter and Full Year 2024 Outlook

Exhibit 99.1 June 4, 2024 Augmedix Reiterates Second Quarter and Full Year 2024 Outlook Management Provides Update in Advance of William Blair Annual Growth Stock Conference Appearance SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) - Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reiterated its expectations in advance of management’s participation at

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 AUGMEDIX, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

Augmedix Delivers 40% Revenue Growth for First Quarter of 2024 SAN FRANCISCO, May 13, 2024 - Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024.

r 9, 2018, by and between Ian Shakil and Augmedix, Inc

AUGMEDIX, INC. 1161 MISSION STREET, SUITE 210 SAN FRANCISCO, CA 94103 October 9, 2018 Ian Shakil Dear Ian, Augmedix, Inc. (the “Company”), is pleased to offer you the following new terms of your continued employment: 1.Position. Beginning October 9, 2018, you will serve in a new full-time capacity as Founding Chairman and Chief Strategy Officer. 2.Compensation. You will be paid a salary at the ann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40890 AUGME

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Amendment 1 to Statement of Work No. 3, dated April 15, 2024, by and between Augmedix Operating Corp., f/k/a Augmedix, Inc. and Sutter Health (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on April 18, 2024)

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. AMENDMENT 1 TO STATEMENT OF WORK STATEMENT OF WORK NO. 3 FOR [***] STAFF AUGMENTATION SUTTER BAY MEDICAL FOUNDATION This Amendment 1 to the Statement of Work dated January 9, 2023 (the “

Tenth Amendment to the Master Service Agreement by and between Augmedix Operating Corp., f/k/a Augmedix, Inc., and Sutter Health, dated April 15, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 18, 2024)

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. SUTTER HEALTH TENTH AMENDMENT TO THE MASTER SERVICES AGREEMENT This Tenth Amendment to the Master Services Agreement (the “Amendment”) is entered into as of April 15, 2024 (the “Effectiv

Seventh Omnibus Amendment, entered into on April 9, 2024, by and among Augmedix Operating Corp., f/k/a Augmedix, Inc., Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 15, 2024)

Exhibit 10.1 SEVENTH OMNIBUS AMENDMENT This Seventh Omnibus Amendment (“Seventh Omnibus Amendment”) is made and entered into as of April 1, 2024 (“Amendment Effective Date”), by and between, on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (“Augmedix”) and, on the other hand, Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

As filed with the Securities and Exchange Commission on March 27, 2024

As filed with the Securities and Exchange Commission on March 27, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Augmedix, Inc.

Amendment to Sublease by and between Augmedix Operating Corp. and Turo Inc., dated October 31, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on November 6, 2023).

LEASE AGREEMENT This LEASE AGREEMENT for lease of Commercial Space # A & B-8 at the 8th floor of the Commercial Complex of Sony Chocolate Industries Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40890 AUGMEDI

ompensation R

Exhibit 97.1 AUGMEDIX, INC. COMPENSATION RECOUPMENT POLICY In the event of any required accounting restatement of the financial statements of Augmedix, Inc. (the “Company”) due to the material noncompliance of the Company with any financial reporting requirement under the applicable U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued

Lease Agreement (17th Floor) by and between Augmedix Bangladesh Ltd. and Sony Chocolate Industries Ltd., dated November 22, 2023

Exhibit 10.41 LEASE AGREEMENT This LEASE AGREEMENT for lease of Commercial Space # C-17 at the 17th floor of the Commercial Complex of Sony Chocolate Industries Ltd. at Rahman’s Regnum Centre, 191/1, Tejgaon-Gulshan Link Road, Tejgaon C/A, Dhaka-1208 is made on this 22 November, 2023 to be effective from 1st March, 2024 (hereinafter the “Lease Agreement”). BETWEEN Sony Chocolate Industries Ltd. a

Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023

Exhibit 99.1 Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023 SAN FRANCISCO, March 18, 2024 — Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three and 12 months ended December 31, 2023. “The fourth quarter was a solid end to a strong year for Augmedix both operationally and

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

AUGX / Augmedix, Inc. / DCM VI, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 tm247299d1sc13da.htm SC 13D/A CUSIP NO. 05105P107 13D Page 1 of 19 Pages SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 7) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

AUGX / Augmedix, Inc. / Samjo Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

AUGX / Augmedix, Inc. / DCM VI, L.P. - SC 13D/A Activist Investment

CUSIP NO. 05105P107 13D Page 1 of 18 Pages SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 6) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) Matthew C. B

AUGX / Augmedix, Inc. / DCM VI, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 tm243067d1sc13da.htm SC 13D/A CUSIP NO. 05105P107 13D Page 1 of 19 Pages SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 5) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 AUGMEDIX, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

Sixth Omnibus Amendment, entered into on January 5, 2024, by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers.

Exhibit 10.1 SIXTH OMNIBUS AMENDMENT This Sixth Omnibus Amendment (“Sixth Omnibus Amendment”) is made and entered into as of January 1, 2024 (“Amendment Effective Date”), by and between, on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (“Augmedix”) and, on the other hand, Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 AUGMEDIX, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

2

Exhibit 99.1 January 5, 2024 Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix Go SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) - Augmedix, Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and d

AUGX / Augmedix, Inc. / DCM VI, L.P. - SC 13D/A Activist Investment

CUSIP NO. 05105P107 13D Page 1 of 13 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 4) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) Matthew C. Bonner

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

AUGX / Augmedix Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-9980 (Name

Form of Lock-Up Agreement by and between William Blair & Company and Robert Faulkner

EX-99.16 3 tm2331315d1ex99-16.htm EXHIBIT 99.16 Exhibit 99.16 Execution Version November 14, 2023 Evercore Group L.L.C. William Blair & Company, L.L.C. as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o Evercore Group L.L.C. 55 East 52nd Street New York, NY 10055 c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illino

Form of Lock-Up Agreement by and among William Blair & Company and the Redmile Funds

EX-99.15 2 tm2331315d1ex99-15.htm EXHIBIT 99.15 Exhibit 99.15 Execution Version November 14, 2023 Evercore Group L.L.C. William Blair & Company, L.L.C. as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o Evercore Group L.L.C. 55 East 52nd Street New York, NY 10055 c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illino

Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare and Redmile Group Provides Incremental Capital to Expand Augmedix’s Commercial Team, while Accelerating Development of Product Roadmap

Exhibit 99.1 Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare and Redmile Group Provides Incremental Capital to Expand Augmedix’s Commercial Team, while Accelerating Development of Product Roadmap to Address New Market Segments SAN FRANCISCO, November 21, 2023 – Augmedix, Inc. (Nasdaq: AUGX), a healthcare technology company that de

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 AUGMEDIX, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

Underwriting Agreement, dated November 15, 2023, by and among Augmedix, Inc., Evercore Group L.L.C. and William Blair & Company, L.L.C

Exhibit 1.1 Augmedix, Inc. (a Delaware corporation) 6,250,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: November 15, 2023 Augmedix, Inc. (a Delaware corporation) 6,250,000 Shares of Common Stock UNDERWRITING AGREEMENT November 15, 2023 Evercore Group L.L.C. William Blair & Company, L.L.C. as Representatives of the several Underwriters Evercore Group L.L.C. 55 East 52nd Street New York,

Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock

Exhibit 99.1 Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock SAN FRANCISCO, November 15, 2023 – Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock. Augm

Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock

Exhibit 99.2 Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock SAN FRANCISCO, November 15, 2023 – Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has priced the previously-announced underwritten public offering of 6,250,000 sha

Augmedix, Inc. 6,250,000 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) File No. 333-264337 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) Augmedix, Inc. 6,250,000 Shares Common Stock We are offering $25,000,000 of shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “AUGX.” The aggregate market value of our outstanding common stock held by non-affiliates on November 9, 2023 was

Investor P r e s e n t a t i o n November 2023 Nasdaq: AUGX

Exhibit 99.1 Investor P r e s e n t a t i o n November 2023 Nasdaq: AUGX This presentation includes forward - looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financial position, business strategy and plans and objectives of management for future operations, are forward - looki

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 AUGMEDIX, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

SUBJECT TO COMPLETION, DATED NOVEMBER 15, 2023

Filed Pursuant to Rule 424(b)(5) File No. 333-264337 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and are not so

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40890 AUGME

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

Amendment to Sublease by and between, Augmedix Operating Corp. and Turo Inc., dated October 31, 2023.

Exhibit 10.1 AMENDMENT TO SUBLEASE THIS AMENDMENT TO SUBLEASE (“Amendment”) is entered into as of October 30, 2023 (the “Amendment Effective Date”), by and between TURO INC., a Delaware corporation (“Sublessor”), and AUGMEDIX OPERATING CORP., a Delaware corporation (“Sublessee”) with reference to the following facts: A. Sublessor and Sublessee are parties to that certain Sublease dated as of Decem

Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023

Exhibit 99.1 Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023 SAN FRANCISCO, November 6, 2023 – Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, reported today financial results for the three and nine months ended September 30, 2023. “The third quarter marked another pe

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

AUGX / Augmedix Inc / DCM VI, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 3) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) Matthew C. Bonner c/o DCM 2420 Sand Hill Road, Suite 20

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

Fifth Omnibus Amendment by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers, dated October 10, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on October 13, 2023).

Exhibit 10.1 FIFTH OMNIBUS AMENDMENT This Fifth Omnibus Amendment (“Fifth Omnibus Amendment”) is made and entered into as of October 1, 2023 (“Amendment Effective Date”), by and between, on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (“Augmedix”) and, on the other hand, Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC

Non-Employer Director Election to Receive Shares in Lieu of Cash under the Augmedix, Inc. 2020 Equity Incentive Plan.

Exhibit 10.10 AUGMEDIX, INC. (the “Company”) Non-Employee Director Election to Receive Shares in Lieu of Cash To be effective with respect to the payment of Board and Committee fees for the third quarter of 2023, this election must be received by Todd Holvick ([email protected], with a copy to [email protected]) by no later than August 11, 2023 (the “Election Date”). Election to Receive Shares Pu

2020 Equity Incentive Plan, as amended and restated, and form of award agreements thereunder.

Exhibit 10.1 AUGMEDIX, INC. 2020 EQUITY INCENTIVE PLAN (as amended and restated effective July 1, 2021) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40890 AUGMEDIX,

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023

Exhibit 99.1 Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023 SAN FRANCISCO, August 7, 2023 – Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2023 AUGMEDIX, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

Fourth Omnibus Amendment, entered into on July 11, 2023, by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on July 14, 2023).

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. FOURTH OMNIBUS AMENDMENT This Fourth Omnibus Amendment (“Fourth Omnibus Amendment”) is made and entered into as of July 1, 2023 (“Amendment Effective Date”), by and between, on the one h

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 AUGMEDIX, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

AUGX / Augmedix Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-9980 (Name

Registration Rights Agreement.

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of June 13, 2023, among Augmedix, Inc., a Delaware corporation (the “Company”) and the persons who have purchased the Securities (as defined below) and have executed counterpart signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers”). Capi

Form of SVB Warrant.

EX-4.1 2 ea179917ex4-1augmedix.htm FORM OF SVB WARRANT Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS

Form of ELOC Warrant.

EX-4.2 3 ea179917ex4-2augmedix.htm FORM OF ELOC WARRANT Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN O

First Amendment to Loan and Security Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 14, 2023).

Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of June 13, 2023, by and between (i) SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon

Securities Purchase Agreement.

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 13, 2023, by and among Augmedix, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide

Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit Balance Sheet Initiatives Bolster Financial Strength as Company Scales Business Towards Cash Flow Break-Even

Exhibit 99.1 Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit Balance Sheet Initiatives Bolster Financial Strength as Company Scales Business Towards Cash Flow Break-Even SAN FRANCISCO, CA (June 14, 2023) – Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation, today announced that it has amended its e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2023 AUGMEDIX, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Augmedix, Inc.

As filed with the Securities and Exchange Commission on June 12, 2023

As filed with the Securities and Exchange Commission on June 12, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 AUGMEDIX, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, California 94104

Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, California 94104 May 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Rucha Pandit Re: Augmedix, Inc. Registration Statement on Form S-3 (File No. 333-272081) Request for Acceleration Dear Ms. Pandit: Pursuant to Rule 461 of the General Rul

As filed with the Securities and Exchange Commission on May 19, 2023

As filed with the Securities and Exchange Commission on May 19, 2023 Registration No.

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-3 (Form Type) Augmedix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 AUGMEDIX, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

Statement of Work by and between Augmedix Operating Corp. and Baylor St. Luke’s Medical Group, dated May 12, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 18, 2023).

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. STATEMENT OF WORK (SOW) This Statement of Work (“SOW”), effective as of the date of the last signature below (the “SOW Effective Date”), is made pursuant to the Services Agreement betwee

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40890 AUGMEDIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 AUGMEDIX, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

Augmedix Delivers Continued Sales Momentum; Reports First Quarter 2023 Financial Results

Exhibit 99.1 Augmedix Delivers Continued Sales Momentum; Reports First Quarter 2023 Financial Results SAN FRANCISCO, Calif. – May 12, 2023 – Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results fo

Investor Presentation 1 May 2023 This presentation includes forward - looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financia

Exhibit 99.2 Investor Presentation 1 May 2023 This presentation includes forward - looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financial position, business strategy and plans and objectives of management for future operations, are forward - looking statements. Forward - l

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 AUGMEDIX, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number)

Statement of Work No.2 by and between Augmedix Operating Corp. f/k/a Augmedix, Inc. and DHMF (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 9, 2023).

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. AUGMEDIX NOTES – STATEMENT OF WORK NO. 2 This Statement of Work (“SOW”), entered into by and between Dignity Health Medical Foundation (a Dignity Health Affiliate) (“DHMF” or “Client”) a

AUGX / Augmedix Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-9980 (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40890 AUGME

Offer letter, dated October 23, 2020, by and between Saurav Chatterjee and Augmedix, Inc.

Exhibit 10.5 Augmedix, Inc. 1161 Mission Street, Suite 210 San Francisco, CA 94103 October 23, 2020 Saurav Chatterjee Via email to: [*] Dear Saurav, Augmedix, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position and Start Date. Beginning November 16, 2020, you will serve in a full-time capacity as Chief Technology Officer. By signing this letter agreement, yo

AUGX / Augmedix Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-9980 (Name

Joint Filing Agreement, dated as of April 21, 2023, by and among Redmile, Jeremy C. Green, Redmile Private Fund Investments II, L.P., RAF, LP, RedCo I, L.P. and RedCo II Master Fund, L.P.

Exhibit 99.7 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.0001 par value per share, of Augmedix, Inc., which

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on April 20, 2023).

Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGIS

Augmedix Announces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation

Exhibit 99.1 Augmedix Announces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation SAN FRANCISCO, CA (April 20, 2023) – Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation, today announced a partnership with HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare provid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2023 AUGMEDIX, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Augmedix Secures Strategic Financing from HCA Healthcare and Redmile Group Company raises $12 million of new equity from HCA Healthcare and Redmile Group; Augmedix and HCA Healthcare to collaborate on AI-powered ambient documentation products for the

Exhibit 99.2 Augmedix Secures Strategic Financing from HCA Healthcare and Redmile Group Company raises $12 million of new equity from HCA Healthcare and Redmile Group; Augmedix and HCA Healthcare to collaborate on AI-powered ambient documentation products for the acute care setting; Provides sufficient capital to achieve cash flow sustainability SAN FRANCISCO, April 20, 2023 - Augmedix Inc. (Nasda

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 20, 2023).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 19, 2023 (the “Effective Date”), by and among Augmedix, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and deliv

Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on April 20, 2023).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of April 19, 2023, among Augmedix, Inc., a Delaware corporation (the “Company”) and the persons who have purchased the Securities (as defined below) and have executed counterpart signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers”). Cap

Form of Breakeven Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on April 20, 2023).

Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGIS

Description of Registrant’s Securities.

Exhibit 4.8 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2022, Augmedix, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the most importa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56036 AUGMEDIX, INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2023 AUGMEDIX, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report o

Augmedix Reports Strong Commercial Traction and Sales Momentum; Reports Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 Augmedix Reports Strong Commercial Traction and Sales Momentum; Reports Fourth Quarter and Full Year 2022 Financial Results SAN FRANCISCO, Calif. –– March 27, 2023 –– Augmedix (Nasdaq: AUGX), a leading provider of ambient medical documentation and data solutions delivered remotely to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported fin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2023 AUGMEDIX, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 AUGMEDIX, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Non-Executive Chairman Agreement between Augmedix, Inc. and Rod O’Reilly dated February 28, 2023.

Exhibit 10.1 Augmedix, Inc. NON-EXECUTIVE CHAIRMAN AGREEMENT This Non-Executive Chairman Agreement (the “Agreement”) is entered into as of the date of the last signature below (the “Effective Date”), by and between Augmedix, Inc., a Delaware corporation (the “Company”), and Rod O’Reilly (“O’Reilly”). The Board of Directors (the “Board”) of the Company desires to have O’Reilly serve as the Non-Exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 AUGMEDIX, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

Augmedix Names Rod O’Reilly as Non- Executive Chairman of the Board of Directors

Exhibit 99.1 March 1, 2023 Augmedix Names Rod O’Reilly as Non- Executive Chairman of the Board of Directors Proven Healthcare Technology Executive Joins Augmedix Board, Committed to Addressing Access, Outcomes and Physician Burnout SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) — Augmedix Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documenta

Ninth Amendment to the Master Service Agreement by and between Augmedix Operating Corp., f/k/a Augmedix, Inc. and Sutter Health, dated February 15, 2023.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. SUTTER HEALTH NINTH AMENDMENT TO THE MASTER SERVICES AGREEMENT This Ninth Amendment (the “Amendment”) is entered into as of February 15, 2023 (the “Effective Date”) by and between SUTTER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 AUGMEDIX, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

US05105P1075 / Augmedix Inc / Tompkins Mark N. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

Lease Agreement by and between, Augmedix Bangladesh Ltd. and Sony Chocolate Industries Ltd., dated January 31, 2023.

Exhibit 10.1

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

US05105P1075 / Augmedix Inc / DCM VI, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) Matthew C. Bonner c/o DCM 2420 Sand Hill Road, Suite 20

Statement of Work No. 3 by and between Augmedix Operation Corp. and Sutter Health, dated January 9, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on January 12, 2023).

EX-10.1 2 ea171608ex10-1augmedix.htm STATEMENT OF WORK NO.3, DATED JANUARY 9, 2023, BY AND BETWEEN AUGMEDIX OPERATING CORP. AND SUTTER HEALTH Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. STATEMENT OF WORK NO. 3 FOR [***] STAFF AUGM

Financial Statements and Exhibits, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 AUGMEDIX, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

Augmedix Exits Calendar 2022 with Expected $35 Million in Annual Recurring Revenue Company Also Expects Fourth Quarter Revenue to be Within the Guidance Range

Exhibit 99.1 Augmedix Exits Calendar 2022 with Expected $35 Million in Annual Recurring Revenue Company Also Expects Fourth Quarter Revenue to be Within the Guidance Range SAN FRANCISCO, Jan. 9, 2023 (GLOBE NEWSWIRE) - Augmedix Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, today announced preliminary financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2023 AUGMEDIX, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2023 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2022 AUGMEDIX, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

Agreement to Lease by and among Augmedix Solutions Pvt. Ltd., Shukoor Habib Trust and Rafeeq Trust, dated December 21, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on December 28, 2022).

Exhibit 10.1 [Seal] AGREEMENT TO LEASE THIS AGREEMENT TO LEASE (the ?Agreement?) executed on the 21st day of December Two Thousand Twenty-Two (21/12/2022) at Bangalore: BE T W E E N: 1) M/S. SHUKOOR HABIB TRUST, A Trust having its office at No.10/9, M.V. Bhadran Street, Periamet, Chennai-600 003 represented by its Trustee, Mr. Kundalam Ifzal Ahmed (hereinafter referred to as the ?Lessor No. I?, wh

Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40890 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

US05105P1075 / Augmedix Inc / McKesson Ventures, LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Augmedix, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 05105P107 (CUSIP Number) Lori A. Schechter Executive Vice President, Chief Legal Officer and General Counsel McKesson Corporation 6555 State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56036 AUGME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report

Augmedix Reports Third Quarter 2022 Financial Results

Exhibit 99.1 Augmedix Reports Third Quarter 2022 Financial Results SAN FRANCISCO, Calif. ? November 14, 2022 ? Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended September 30, 2022. ?We are pleased with our record third quarter as it serves as a testament to the market?s accelerating ad

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

Statement of Work by and between Augmedix Operating Corp. and St. Joseph Physician Associates, d/b/a St. Joseph Medical Group, effective as of October 31, 2022 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on November 2, 2022).

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. STATEMENT OF WORK (SOW) This Statement of Work (?SOW?), effective as of the date of the last signature below (the ?SOW Effective Date?), is made pursuant to the Services Agreement betwee

Assignment Amendment by and between Dignity Health and Common Spirit Health (f/k/a Catholic Health Initiative) and Augmedix Operating Corp. f/k/a Augmedix, Inc. effective as of October 20, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on November 2, 2022).

Exhibit 10.1 ASSIGNMENT AMENDMENT TO THE SERVICES AGREEMENT Contract Number DH-IT-1186 This Assignment Amendment (the ?Amendment?) is made effective this October 20, 2022 (the ?Amendment Effective Date?) by and between, on the one hand, Dignity Health, a California non-profit, public benefit corporation, and CommonSpirit Health (f/k/a Catholic Health Initiatives), a Colorado non-profit corporation

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

US05105P1075 / Augmedix Inc / McKesson Ventures, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Augmedix, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 05105P107 (CUSIP Number) Lori A. Schechter Executive Vice President, Chief Legal Officer and General Counsel McKesson Corporation 6555 State Hwy 161

Investor Presentation September 2022 This presentation includes forward - looking statements. All statements other than statements of historical facts contained in the se materials or elsewhere, including statements regarding the Company’s future fin

Exhibit 99.1 Investor Presentation September 2022 This presentation includes forward - looking statements. All statements other than statements of historical facts contained in the se materials or elsewhere, including statements regarding the Company?s future financial position, business strategy and plans and objectives of management for future operations, are for ward - looking statements. Forwa

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File

US05105P1075 / Augmedix Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES& EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-9980 (Name,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 1, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File N

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Num

Letter of Frank, Rimerman + Co. LLP to the Securities and Exchange Commission dated August 22, 2022 (incorporated by reference to Exhibit 16.1 to the Current Report on Form 8-K filed with the SEC on August 23, 2022).

Exhibit 16.1 August 22, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Augmedix Inc. Form 8-K dated August 22, 2022 and we agree with the statements made therein. Yours truly, /s/ Frank, Rimerman + Co. LLP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56036 AUGMEDIX,

Investor Presentation August 2022 This presentation includes forward - looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financi

Exhibit 99.2 Investor Presentation August 2022 This presentation includes forward - looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company?s future financial position, business strategy and plans and objectives of management for future operations, are forward - looking statements. Forward -

Augmedix Reports Second Quarter 2022 Financial Results

Exhibit 99.1 Augmedix Reports Second Quarter 2022 Financial Results SAN FRANCISCO, Calif. ? August 8, 2022 ? Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended June 30, 2022. ?This quarter, we continued to see good momentum and are pleased with our strong start to 2022. We remain focuse

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Augmedix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry

Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, California 94104 July 27, 2022

Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, California 94104 July 27, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Augmedix, Inc. Registration Statement on Form S-3 File No. 333-266299 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended (the ?Securiti

As filed with the Securities and Exchange Commission on July 27, 2022

POS AM 1 ea163329-posamaugmedix.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 As filed with the Securities and Exchange Commission on July 27, 2022 Registration No. 333- 251310 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Augmedix, Inc. (Exact name

As filed with the Securities and Exchange Commission on July 22, 2022

As filed with the Securities and Exchange Commission on July 22, 2022 Registration No.

As filed with the Securities and Exchange Commission on July 22, 2022

S-8 1 ea163111-s8augmedixinc.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 83-3299164 (State or other jurisdict

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Augmedix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Augmedix, Inc.

Statement of Work No. 3 by and between Augmedix Operating Corp. and Infosense Technologies, Pvt. Ltd. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on July 13, 2022).

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. Statement of Work No. 3 This Statement of Work No. 3 (?SOW No. 3?), dated June 1, 2022 (?Effective Date?), replaces the Statement of Work No. 2 by and between Infosense Technologies, Pvt

Statement of Work No. 4 by and between Augmedix Operating Corp. and IDS Infotech Ltd. dated June 1, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on July 13, 2022).

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED. Statement of Work No. 4 This Statement of Work No. 4 (?SOW No. 4?), dated June 1, 2022 (?Effective Date?), replaces the Statement of Work No. 3 by and between IDS Infotech Ltd. (?Service

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number

Third Omnibus Amendment by and among Augmedix Operating Corp. f/k/a Augmedix, Inc. Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers dated June 9, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 10, 2022).

Exhibit 10.1 THIRD OMNIBUS AMENDMENT This Third Omnibus Amendment (?Third Omnibus Amendment?) is made and entered into as of July 1, 2022 (?Amendment Effective Date?), by and between, on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (?Augmedix?) and, on the other hand, Dignity Health (?DH?), Dignity Health Medical Foundation (?DHMF?), and Pacific Central Coast Health Centers (?PHC? a

Open Market Sale AgreementSM, dated as of May 24, 2022, by and between Augmedix, Inc. and Jefferies LLC.

EX-1.1 2 ea160368ex1-1augmedix.htm OPEN MARKET SALE AGREEMENTSM, DATED AS OF MAY 24, 2022, BY AND BETWEEN AUGMEDIX, INC. AND JEFFERIES LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 24, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Augmedix. Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue a

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction (Commission (I.R.S. Employer of incorpora

Augmedix, Inc. Up to $25,000,000 Common Stock

424B5 1 f424b50522augmedix.htm Filed Pursuant to Rule 424(b)(5) File No. 333-264337 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) Augmedix, Inc. Up to $25,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the “sales agreement”), with Jefferies LLC (“Jefferies”), dated May 24, 2022, relating to the sale of shares of our common stock offered by this prospectus supp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56036 AUGMEDIX,

Augmedix Reports First Quarter 2022 Financial Results

Exhibit 99.1 Augmedix Reports First Quarter 2022 Financial Results SAN FRANCISCO, Calif. ? May 9, 2022 ? Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended March 31, 2022. Manny Krakaris, Chief Executive Officer of Augmedix, commented, ?We are pleased with our start to 2022 as we contin

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number)

Warrant to Purchase Stock by and between Augmedix, Inc. and Silicon Valley Bank dated May 4, 2022 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 5, 2022).

Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTA

Loan and Security Agreement by and among Augmedix, Inc., Augmedix Operating Corporation and Silicon Valley Bank dated as of May 4, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 5, 2022).

Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrowers listed on Schedule I hereto (?Borrowers?). The parties agree as follows: 1. LOAN AND TERMS OF PAYMENT 1.1 Revolving Line. (a) Availability. Subject to (i) the terms and conditions of this Agr

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Number)

Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, California 94104

CORRESP 1 filename1.htm Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, California 94104 May 3, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Janice Adeloye Re: Augmedix, Inc. Registration Statement on Form S-3 (File No. 333-264337) Request for Acceleration Dear Ms. Adeloye: Pursuant to R

Definitive Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant R Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Deed of Quadripartite Agreement by and among, Augmedix Bangladesh Ltd., Amin Mohammad Foundation Ltd. and Amin Mohammad Property Management Services Ltd. and the landlords set forth therein.

Exhibit 10.1 [signatures of parties] Bismillahir Rahmanir Rahim QUADRIPARTITE AGREEMENT This DEED OF QUADRIPARTITE AGREEMENT (hereinafter referred to as the ?Agreement?) is made in Dhaka, Bangladesh on this the 18th day of April 2022 of the Christian era and shall be effective from the 18TH day of April, 2022 (?Effective Date?). AMONG (1) Sabuz Banik (Owner of 10th Floor, Type: A, Area: 5668 Sft),

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-3 (Form Type) Augmedix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F

Form of Indenture.

Exhibit 4.3 AUGMEDIX, INC., as Issuer and [ ], as Trustee INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES CROSS-REFERENCE TABLE Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939, as amended: Trust Indenture Act Section Indenture Section 310(a)(1) 7.09; 7.10 (a)(2) 7.10 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 7.10 (b)

As filed with the Securities and Exchange Commission on April 15, 2022

As filed with the Securities and Exchange Commission on April 15, 2022 Registration No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Augmedix Names William Febbo as New Member to its Board of Directors William Febbo, CEO and Director of OptimizeRx, joins the Augmedix Board of Directors

Exhibit 99.1 Augmedix Names William Febbo as New Member to its Board of Directors William Febbo, CEO and Director of OptimizeRx, joins the Augmedix Board of Directors SAN FRANCISCO, Calif. ? March 29, 2022 ? Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced that William Febbo, Chief Executive Officer and Director of OptimizeRx,

Exhibit 4.8

Exhibit 4.8 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2021, Augmedix, Inc. (the ?Company,? ?we,? or ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description summarizes the most importa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56036 AUGMEDIX, INC. (Exact nam

Augmedix Reports Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 Augmedix Reports Fourth Quarter and Full Year 2021 Financial Results SAN FRANCISCO, Calif. ?? Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended December 31, 2021. ?We are pleased with the progress we made in 2021, as we continued to execute well across our strategic initia

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numb

Augmedix Announces New Board Member, Laurie McGraw Laurie McGraw, Former Allscripts Executive, Joins the Augmedix Board of Directors

Exhibit 99.1 Augmedix Announces New Board Member, Laurie McGraw Laurie McGraw, Former Allscripts Executive, Joins the Augmedix Board of Directors SAN FRANCISCO, Calif. ? March 10, 2022 ? Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced that Laurie McGraw, a former Allscripts Executive, has joined its board of directors, effecti

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Numbe

March 1, 2022

Exhibit 99.1 March 1, 2022 Augmedix to Participate at the 2022 JMP Securities Technology Conference SAN FRANCISCO, March 01, 2022 (GLOBE NEWSWIRE) - Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco. Manny Krakaris, Chief Executi

Investor Presentation JMP Securities Technology Conference San Francisco M a r c h 8 , 2 0 2 2 This presentation includes forward-looking statements . All statements other than statements of historical facts contained in these materials or elsewhere,

Exhibit 99.2 Investor Presentation JMP Securities Technology Conference San Francisco M a r c h 8 , 2 0 2 2 This presentation includes forward-looking statements . All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company?s future financial position, business strategy and plans and objectives of management for fut

US05105P1075 / Augmedix Inc / Tompkins Mark N. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2022 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

Augmedix Announces Preliminary Fourth Quarter 2021 Financial Results

Exhibit 99.1 Augmedix Announces Preliminary Fourth Quarter 2021 Financial Results SAN FRANCISCO, Calif. - January 31, 2022 - Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced preliminary unaudited financial and operational results for the three months ended December 31, 2021. ?We are very pleased with how 2021 concluded, a

29,174,239 Shares of Common Stock

Filed pursuant to Rule 424(b)(3) Registration No. 333 ? 251310 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated February 8, 2021, as previously amended) 29,174,239 Shares of Common Stock This prospectus supplement supplements the prospectus dated February 8, 2021, as previously amended (the ?Prospectus?), which forms a part of our registration statement on Form S-1 (No. 333-251310). This prospectu

AUGX / AUGMEDIX INC COM / DCM VI, L.P. - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Augmedix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05105P107 (CUSIP Number) Matthew C. Bonner c/o DCM 2420 Sand Hill Road, Suite 20

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

Augmedix Partners with the National Cooperative of Health Networks Association Virtual healthcare service and health association partner to reduce the burden of documentation across rural health networks

Exhibit 99.1 Augmedix Partners with the National Cooperative of Health Networks Association Virtual healthcare service and health association partner to reduce the burden of documentation across rural health networks SAN FRANCISCO, CA, November 9, 2021 ? Augmedix, Inc. (Nasdaq: AUGX), a leading digital health platform that offers virtual medical documentation and live clinical support, and the Nat

Company Overview N o vem ber 2021 This presentation includes forward-looking statements . All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financia

EX-99.2 3 ea150326ex99-2augmedix.htm AUGMEDIX INVESTOR PRESENTATION NOVEMBER 2021 Exhibit 99.2 Company Overview N o vem ber 2021 This presentation includes forward-looking statements . All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financial position, business strategy and plans and objectives

Augmedix Reports Third Quarter 2021 Financial Results

Exhibit 99.1 Augmedix Reports Third Quarter 2021 Financial Results SAN FRANCISCO, Calif. ? November 9, 2021 ? Augmedix, Inc. (Nasdaq: AUGX), a leading digital health platform that offers virtual medical documentation and live clinical support, today reported financial results for the three months ended September 30, 2021. ?In the third quarter, we delivered strong revenue growth and steady gross m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56036 AUGME

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

Lock-Up Agreement by and between William Blair & Company and Gerard van Hamel Platerink, dated October 25, 2021

Exhibit 99.6 October 25, 2021 Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, CA 94104 William Blair & Company, L.L.C., As Representative of the Several Underwriters, c/o William Blair & Company, L.L.C. 150 North Riverside Plaza, Chicago, IL 60606 Re: Proposed Public Offering of Augmedix, Inc. Common Stock Ladies and Gentlemen: As an inducement to the underwriters (the ?Underwriters?)

AUGX / AUGMEDIX INC COM / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES& EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Augmedix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05105P 107 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal Department

Lock-Up Agreement by and among William Blair & Company and the Redmile Funds, dated October 25, 2021

Exhibit 99.5 October 25, 2021 Augmedix, Inc. 111 Sutter Street, Suite 1300 San Francisco, CA 94104 William Blair & Company, L.L.C., As Representative of the Several Underwriters, c/o William Blair & Company, L.L.C. 150 North Riverside Plaza, Chicago, IL 60606 Re: Proposed Public Offering of Augmedix, Inc. Common Stock Ladies and Gentlemen: As an inducement to the underwriters (the ?Underwriters?)

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu

Underwriting Agreement, dated October 25, 2021, by and among Augmedix, Inc., and William Blair & Company, L.L.C., as representative of the underwriters listed on Schedule I thereto

Exhibit 1.1 Execution Version Common Stock, par value $0.0001 per share Underwriting Agreement October 25, 2021 William Blair & Company, L.L.C. As representative of the several Underwriters named in Schedule I hereto, c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Augmedix, Inc., a Delaware corporation (the ?Company?), proposes, subject

$40,000,000 Common Stock

Filed Pursuant to Rule 424(b)(4) Registration No. 333-259331 PROSPECTUS $40,000,000 Common Stock We are offering $40,000,000 of shares of our common stock. Our common stock is traded on the over-the-counter market and quoted on the OTCQX market under the symbol ?AUGX.? On October 1, 2021, the last reported sale price of our common stock was $6.00 per share. The final public offering price of the s

Augmedix, Inc. Announces Uplisting to Nasdaq and Pricing of Public Offering of $40,000,000 of Common Stock

Exhibit 99.1 Augmedix, Inc. Announces Uplisting to Nasdaq and Pricing of Public Offering of $40,000,000 of Common Stock SAN FRANCISCO, Calif. ? October 25, 2021 ? Augmedix, Inc. (Nasdaq: AUGX) (?Augmedix?), a leading provider of virtual medical documentation and live clinical support, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock (?Common S

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 AUGMEDIX, INC. (Exact name of registrant as specified in its charter) Delaware 000-56036 83-3299164 (State or other jurisdiction of incorporation) (Commission File Nu